Commentaries
16 April 2025
Vol. 4 No. 2 (2025)
Comment on "Apixaban vs. aspirin for stroke prevention in people with subclinical atrial fibrillation and a history of stroke or transient ischemic attack: subgroup analysis of the ARTESiA randomized controlled trial"
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
141
Views
40
Downloads
Authors
I read with interest the subgroup analysis of the ARTESiA trial recently published in Lancet Neurology....
Altmetrics
Downloads
Download data is not yet available.
Citations
1. Shoamanesh A, Field TS, Coutts SB, et al. Apixaban versus aspirin for stroke prevention in people with subclinical atrial fibrillation and a history of stroke or transient ischaemic attack: subgroup analysis of the ARTESiA randomised controlled trial. Lancet Neurol 2025;24:140-51. DOI: https://doi.org/10.1016/S1474-4422(24)00475-7
2. Healey JS, Connolly SJ, Gold MR, et al. Subclinical atrial fibrillation and the risk of stroke. N Engl J Med 2012;366:120-9. DOI: https://doi.org/10.1056/NEJMoa1105575
3. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991;22:983-8. DOI: https://doi.org/10.1161/01.STR.22.8.983
4. Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J 2016;37:2893-962. DOI: https://doi.org/10.5603/KP.2016.0172
5. Healey JS, Lopes RD, Granger CB, et al. Apixaban for stroke prevention in subclinical atrial fibrillation. N Engl J Med 2024;390:107-17. DOI: https://doi.org/10.1056/NEJMc2401632
6. McIntyre WF, Benz AP, Becher N, et al. Direct oral anticoagulants for stroke prevention in patients with device-detected atrial fibrillation: a study-level meta-analysis of the NOAH-AFNET 6 and ARTESiA Trials. Circulation 2024;149:981-8. DOI: https://doi.org/10.1161/CIRCULATIONAHA.123.067512
7. Kirchhof P, Toennis T, Goette A, et al. Anticoagulation with edoxaban in patients with atrial high-rate episodes. N Engl J Med 2023;389:1167-79. DOI: https://doi.org/10.1056/NEJMoa2303062
8. Joglar JA, Chung MK, Armbruster AL, et al. 2023 ACC/AHA/ACCP/HRS guideline for the diagnosis and management of atrial fibrillation: a report of the American College of Cardiology/American Heart Association Joint Committee on clinical practice guidelines. Circulation 2024;149:e1-e156. DOI: https://doi.org/10.1161/CIR.0000000000001218
9. Rubiera M, Aires A, Antonenko K, et al. European Stroke Organisation (ESO) guideline on screening for subclinical atrial fibrillation after stroke or transient ischaemic attack of undetermined origin. Eur Stroke J 2022;7:VI. DOI: https://doi.org/10.1177/23969873221099478
How to Cite
Comment on "Apixaban vs. aspirin for stroke prevention in people with subclinical atrial fibrillation and a history of stroke or transient ischemic attack: subgroup analysis of the ARTESiA randomized controlled trial". (2025). Bleeding, Thrombosis and Vascular Biology, 4(2). https://doi.org/10.4081/btvb.2025.179
Copyright (c) 2025 The Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.
